Allergan has entered into a licensing agreement with MedImmune, AstraZeneca’s global biologics R&D arm, for the global rights to MEDI2070, an anti-IL-23 monoclonal antibody currently in Phase II development for the treatment of moderate-to-severe Crohn’s disease and ulcerative colitis and other related conditions.   AstraZeneca will receive $250 million upfront and potential payments of as much as $1.27 billion, including launch milestones of up to $435 million and sales-based ...